Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Achaogen Inc (NDAQ:AKAO) “Buy” Rating Reconfirmed by Analysts at Stifel Nicolaus; With $28.00 Target

Stifel Nicolaus Analyst Rating Change Achaogen Inc NDAQ:AKAO

Achaogen Inc (NDAQ:AKAO) Rating Kept

EU: In analysts report issued on Wednesday, 15 March, Stifel Nicolaus restate their “Buy” rating on shares of Achaogen Inc (NDAQ:AKAO). They currently have a $28.00 target price on the company. Stifel Nicolaus’s target indicates a potential upside of 20.43 % from the company’s last stock close.

NDAQ:AKAO is now trading -11.29% lower at $22.40 as of 8:02 AM New York time. Achaogen Inc’s stock is 0% over the past 200 days. It has underperformed the S&P 500 Index, which has surged 13.17% over the same time.

Out of 6 analysts covering Achaogen Inc, 4 rate it a Buy, 2 indicate a Hold while 0 suggest a Sell. The highest target is $31 and the lowest is $7 according to Thomson/First Call. The 12-month mean target is $14.17, which means downside potential of 36.74% over the current price.

AKAO Stock Chart

Institutional Ownership

Ecor1 Capital Llc had the biggest stake with ownership of 1.68 million shares as of Q2 2015 for 2.47% of the stock exposure. Nea Management Company Llc is another very bullish investment manager who is having 4.72 million shares of Achaogen Inc or 1.01% of their stock exposure. Also, Sphera Funds Management Ltd. have 1.01% of their stock exposure invested in the company for 1.30 million shares. The New York-based fund Spark Investment Management Llc revealed it had purchased so far a stake worth about 0.06% of the investment manager’s stock portfolio in Achaogen Inc. The Cayman Islands-based fund Cqs Cayman Lp is also positive about the stock, possessing 143,865 shares or 0.04% of their stock exposure.

Achaogen Inc (NDAQ:AKAO) Profile

Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).

Achaogen Inc (NDAQ:AKAO) traded down -11.29% on 15 March, hitting $22.4. A total of 4.84M shares of the company’s stock traded hands. This is up from average of 963,942 shares. Achaogen Inc has a 52 week low of $2.59 and a 52 week high of $27.79. The company has a market cap of $716.79M and a P/E ratio of 0.

Get the latest Achaogen Inc (NDAQ:AKAO) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Achaogen Inc (NDAQ:AKAO) “Buy” Rating Reconfirmed by Analysts at Stifel Nicolaus; With $28.00 Target appeared first on Octafinance.

This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Achaogen Inc (NDAQ:AKAO) “Buy” Rating Reconfirmed by Analysts at Stifel Nicolaus; With $28.00 Target


Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription